Syndax Pharmaceuticals achieved revenue of $73 million for the second quarter, a notable 92% increase year-over-year. This surge reflects the success of its products, particularly Revuforj and Niktimvo, making it an attractive option for investors as the company approaches significant clinical data releases.
Key Highlights
- Syndax recorded net revenue of $54.7 million from Revuforj, representing a 91% increase year-over-year.
- Niktimvo contributed net revenue of $60.3 million, up 67% year-over-year, with collaboration revenue at $18.1 million.
- The company's short interest was 23% of shares outstanding, with 9.8 days to cover as of July 15.
Syndax Pharmaceuticals (NASDAQ: SNDX) reported second-quarter revenue of $73 million, a remarkable 92% surge compared to the same quarter last year. This growth was primarily driven by strong performances of its key products, revumenib (Revuforj) and axatilimab (Niktimvo), with net revenues from each product reaching $54.7 million and $60.3 million, respectively. The comparative anchor highlights an earnings per share (EPS) of $-0.55, slightly missing the consensus estimate of $-0.45.
The positive trajectory reflects not only increased sales but also the growing market acceptance of Syndax's therapies.
Solid Financial Performance
Total revenue for the quarter reached $73 million, significantly up from last year’s figures, primarily due to strong sales of both Revuforj and Niktimvo. Revuforj's net revenue climbed 91% year-over-year, reflecting strong demand for its treatment in the relapsed or refractory acute myeloid leukemia (R/R AML) market. The product's increasing average treatment duration, coupled with an expanding patient pool, solidifies Syndax’s competitive position.
Meanwhile, Niktimvo also experienced substantial growth, with its net revenue up 67%, indicating a positive trend in the chronic graft-versus-host disease (cGVHD) sector. Such consistent revenue enhancements not only elevate the company's market standings but also heighten investor confidence in its therapeutic advancements.
Pipeline Expansion and Future Catalysts
Syndax maintains a promising development pipeline, which includes a next-generation menin inhibitor for myelofibrosis and a novel allosteric EGFR inhibitor intended for non-small cell lung cancer (NSCLC). As of now, Revuforj is seeing traction with over 1,500 total prescriptions, marking a 121% increase year-over-year. The upcoming Phase 2 trial results for axatilimab in idiopathic pulmonary fibrosis (IPF) and frontline cGVHD, scheduled for the fourth quarter of 2026, are highly anticipated and are expected to provide critical data that could further enhance growth prospects.
The drug development milestones signal a solid trajectory toward potential profitability, underscoring the strategic vision of the company.
Market Context and Stock Performance
The stock’s volatility has been met with a short interest volume of 23%, suggesting a market cautious about its near-term performance amidst ongoing clinical updates. Market capitalization stands at approximately $1.7 billion, anchoring Syndax’s strong financial outlook against its competitive environment. While sector peers like GENB remained little changed, and RXRX noted a modest 0.6% gain, the competitive dynamics will be important as the company releases further clinical and operational updates.
With significant data expected in the upcoming months, particularly the Phase 2 results in the fourth quarter, investor attention is likely to increase as they evaluate Syndax's potential to capitalize on its growing portfolio and strategically positioned assets.
Peers Moving on This News
- Generate Biomedicines Inc (GENB) little changed
- Recursion Pharmaceuticals Inc (RXRX) up 0.6%
- Sarepta Therapeutics Inc (SRPT) little changed
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...